Ursolic acid (UA) is a natural pentacyclic triterpenoid carboxylic acid that exerts antidepressant-like effects in the tail suspension test (TST) and in the forced swimming test, and this effect was reported to be mediated by the dopaminergic system. Many studies show that currently available antidepressant agents have effects on multiple neurotransmitter systems which account for their efficacy. Therefore, this study was aimed at investigating the possible involvement of the serotonergic, noradrenergic, glutamatergic and opioid systems in the antidepressant-like effect of UA. To this end, several pharmacological agents were administered to verify their ability to influence the antidepressant-like responses elicited by UA in the TST in mice. The open-field test was used to assess the locomotor activity. The results show that the pre-treatment of mice with ρ-chlorophenylalanine (100 mg/kg, i.p., 4 days) or α-methyl-ρ-tyrosine (100 mg/kg, i.p.) but not with N-methyl-D-aspartate (0.1 pmol/mouse, i.c.v.) or naloxone (1 mg/kg, i.p.), was able to prevent the antidepressant-like effect of UA (0.1 mg/kg, p.o.). Sub-effective doses of fluoxetine (5 mg/kg, p.o.) or reboxetine (2 mg/kg, p.o.), but not ketamine (0.1 mg/kg, i.p.) or MK-801 (0.001 mg/kg, p.o.), was capable of potentiating the effect of a sub-effective dose of UA (0.001 mg/kg, p.o.) in the TST. None of the treatments affected locomotor activity. Altogether, the results show an involvement of the serotonergic and noradrenergic systems, but not the glutamatergic or opioid systems, in the antidepressant-like effect of UA.
Introduction
Major depression is one of the most commonly diagnosed neuropsychiatric disorders, with a worldwide lifetime prevalence of approximately 17% (Greenberg et al., 2003) . By the year 2030, it is estimated that depression will account for the second greatest increase in morbidity. Therefore, it is a chronic, recurring and potentially life threatening disorder that represents a significant socioeconomic burden (Branchi et al., 2013; Mathers and Loncar, 2006) .
Many studies reveal important roles for monoaminergic systems in the pathophysiology and treatment of depression. Particularly monoaminergic neurotransmitters, serotonin, norepinephrine and dopamine, exert major influence on brain circuits implicated in the regulation of mood (Dell'Osso et al., 2011; Elhwuegi, 2004; Hamon and Blier, 2013; Schildkraut, 1965) . Indeed, the antidepressant pharmacotherapy is still based almost exclusively on the drugs that enhance monoamine transmitter function as selective serotonin reuptake inhibitors, selective noradrenaline reuptake inhibitors, tricyclics and monoamine oxidase inhibitors (Hamon and Blier, 2013; Nemeroff and Owens, 2002) .
Besides the monoaminergic system, the glutamatergic and opioid systems have been proposed to be implicated in the etiology of depressive disorder and efforts have been done for searching novel antidepressant agents that modulate these systems (Jutkiewicz and Roques, 2012; Lang and Borgwardt, 2013) . In line with this, studies have reported the antidepressant-like effect of different pharmacological agents that act as N-methyl-D-aspartate (NMDA) receptor antagonists (Machado-Vieira et al., 2012; Salvadore and Singh, 2013) . Interestingly, ketamine, a non-competitive NMDA receptor antagonist, has been reported to exhibit a rapid antidepressant action in preclinical and clinical studies (Salvadore and Singh, 2013; Zarate et al., 2013) . Furthermore, evidence also supports the notion that the activation of the opioid system is implicated in the mechanisms underlying the effect of antidepressant compounds (Brocardo et al., 2009; Schreiber et al., 2002) .
Similar to antidepressants, a natural pentacyclic triterpenoid carboxylic acid, ursolic acid (UA), elicits an antidepressant-like effect in the tail suspension test (TST) and forced swimming test, two different behavioral tests usually performed to screen antidepressant effects of compounds. This effect was reported to be mediated, at least in part, by the dopaminergic system through the activation of dopamine D 1 and D 2 receptors (Machado et al., 2012b) . Moreover, UA produces antinociceptive effect involving serotonergic system (Verano et al., 2013) as well as anti-inflammatory and antitumor activities (Liu, 1995; Lu et al., 2010; Zang et al., 2014) . However, the exact mechanism and neurotransmitter systems involved in the antidepressant-like effect of UA have not been investigated.
Taking into account that many studies have shown that currently available antidepressant agents have effects on multiple neurotransmitter systems that account for their antidepressant efficacy (Hamon and Blier, 2013) , the aim of this study was to explore the putative involvement of the serotonergic, noradrenergic, glutamatergic and opioid systems in the antidepressant-like effect of UA in the TST in mice.
Methods

Animals
Swiss mice (35-45 g, 55-60 days old) of either sex (homogeneously distributed among groups) obtained from the Central Biothery of Universidade Federal de Santa Catarina (UFSC) were used. They were housed in groups of fourteen animals per plastic cage under controlled conditions of light (lights on at 07:00 h) and temperature (20-22°C) with free access to water and food. Mice were allowed to acclimatize to the holding room for 24 h before the behavioral procedure. All manipulations were conducted in the light phase (n = 8 animals per group). All procedures were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Ethics Committee of the Institution.
Drugs
The following drugs were used: ursolic acid, DL-ρ-chlorophenylalanine ethyl ester (PCPA), fluoxetine, α-methyl-ρ-tyrosine (AMPT), N-methyl-D-aspartate (NMDA), ketamine hydrochloride, naloxone hydrochloride (Sigma Chemical Co, St. Louis, MO, USA), MK-801 hydrogen maleate (RBI, Natick, MA, USA) and reboxetine mesylate (Pfizer, SP, Brazil). UA was dissolved in distilled water with 10% of Tween 80. Fluoxetine, reboxetine and MK-801 were dissolved in distilled water, AMPT was dissolved in saline with 10% Tween 80, whereas all the other drugs were dissolved in isotonic saline solution (NaCl 0.9%).
Tail suspension test (TST)
Mice were suspended 50 cm above the floor by adhesive tape placed approximately 1 cm from the tip of the tail. The total duration of immobility was recorded during a 6 min period and a decreased immobility time is considered an antidepressant-like effect according to the method previously described (Steru et al., 1985) . Mice were considered immobile only when they hang passively or stay completely motionless. The immobility time was recorded in real time by an investigator present in the behavioral room that was blind to the experimental groups.
Open-field test
In order to rule out the possibility that the alteration in the immobility time in the TST was due to interference of the locomotor activity, mice were individually submitted to the open-field test paradigm, a wooden box (40 × 60 × 50 cm) with the floor divided into 12 equal squares. The number of crossings in the squares with the four paws was registered during a period of 6 min. The floor of the open-field test apparatus was cleaned with 10% ethanol between tests (Rodrigues et al., 2002) . The number of crossings was recorded in real time by an investigator present in the behavioral room that was blind to the experimental groups.
Pharmacological treatments
To assess if the antidepressant-like effect of UA in the TST involves the serotonergic system, mice were administered with PCPA (100 mg/kg, intraperitoneal injection, i.p., inhibitor of tryptophan hydroxylase, involved in the serotonin synthesis) or vehicle once daily for 4 consecutive days. Thirty minutes after the last PCPA administration, mice received vehicle or UA (0.1 mg/kg, oral administration, p.o.) and, after 60 min, were submitted to the TST or open-field test. In another set of experiments, the effect of the administration of a sub-effective dose of UA (0.001 mg/kg, p.o.), followed by the immediate administration of a sub-effective dose of fluoxetine (5 mg/kg, p.o., a selective serotonin reuptake inhibitor), was investigated 60 min later in the TST or open-field test. The sub-effective dose of fluoxetine was selected based on a dose-response curve in which mice were administered with fluoxetine (5 and 10 mg/kg, p.o.) and, after 60 min, submitted to the TST or open-field test.
In the experiments designed to study a possible role of the noradrenergic system in the antidepressant-like effect of UA, mice were pretreated with AMPT (100 mg/kg, i.p., an inhibitor of tyrosine hydroxylase, a critical enzyme for the synthesis of noradrenaline and dopamine), or vehicle 4 h before UA administration (0.1 mg/kg, p.o.). After 60 min, the behavioral tests were carried out. In another set of experiments, the effect of the administration of a sub-effective dose of UA (0.001 mg/kg, p.o.), followed by the administration of a sub-effective dose of reboxetine (2 mg/kg, p.o., a selective noradrenaline reuptake inhibitor), was investigated after 60 min in the behavioral tests. The sub-effective dose of reboxetine was selected based on a dose-response curve in which mice were administered with reboxetine (2 and 20 mg/kg, p.o.) and, after 60 min, submitted to the TST or openfield test.
To evaluate whether an inhibition of NMDA receptors is implicated in the antidepressant-like effect of UA in the TST, mice were treated with UA (0.1 mg/kg, p.o.) or vehicle and after 45 min, NMDA (0.1 pmol/mouse, i.c.v., a selective agonist of NMDA receptors) or vehicle was administered. Fifteen minutes later, the behavioral tests were carried out. In another set of experiments the effect of the combined administration of UA with ketamine was investigated. Mice were treated with a sub-effective dose of UA (0.001 mg/kg, p.o.) 30 min before the treatment with a sub-effective dose of ketamine (0.1 mg/kg, i.p., a non-competitive NMDA receptor antagonist) and the behavioral tests were performed after 30 min. We also investigated the effect of the combined administration of a sub-effective dose of UA (0.001 mg/kg, p.o.) with a sub-effective dose of MK-801 (0.001 mg/kg, p.o., a non-competitive NMDA receptor antagonist). In this protocol, MK-801 or vehicle was administered immediately after UA or vehicle and 60 min later the behavioral tests were carried out.
To investigate a possible involvement of the opioid system in the antidepressant-like effect of UA, mice were pretreated with naloxone (1 mg/kg, i.p., a nonselective opioid receptor antagonist), or vehicle, 15 min before the administration of UA (0.1 mg/kg, p.o.). Sixty minutes later the behavioral tests were performed.
All drugs were administered in a constant volume of 10 ml/kg body weight and the control animals received appropriate vehicle, except NMDA which was administered by i.c.v. route (5 μl/mouse). The dose of NMDA was chosen based on a dose-response curve carried out by our group in which NMDA caused neither overt signs of toxicity nor alteration in the locomotor activity. The administration schedule and the doses of the drugs used, including the sub-effective and effective dose of UA, were chosen based on experiments previously performed in our laboratory and literature data confirm the efficacy of the abovementioned protocols (Berrocoso et al., 2013; Bettio et al., 2012; Cunha et al., 2013a,b; Machado et al., 2008 Machado et al., , 2012b ).
I.c.v. administration
I.c.v. administration was performed using a microsyringe (25 μl, Hamilton) connected to a 26-gauge stainless-steel needle that was inserted perpendicularly 2 mm deep through the skull (Laursen and Belknap, 1986) . Briefly, the animals were lightly anesthetized with ether (i.e. just that necessary for the loss of the postural reflex) and then gently restrained by hand for i.c.v. injections. The sterilization of the injection site was carried out using gauze embedded in 70% ethanol. The needle was inserted unilaterally 1 mm into the midline point equidistant from each eye, at an equal distance between the eyes and the ears and perpendicular to the plane of the skull. A volume of 5 μl of sterile saline (vehicle) or drugs (dissolved in sterile saline) was injected directly into the left lateral ventricle. Mice exhibited normal behavior within 1 min after injection (Cunha et al., 2013a) .
Statistical analysis
All experimental results are given as mean ± S.E.M. Comparisons between experimental and control groups were performed by one or two-way ANOVA followed by Newman-Keuls post-hoc test when appropriate. A value of P b 0.05 was considered to be significant. 
Results
3.1. Involvement of the serotonergic system in the antidepressant-like effect of UA in the TST Fig. 1A shows that UA alone reduced the immobility time in the TST indicating that it exerts an antidepressant-like effect. The treatment with PCPA alone did not modify the immobility time, but was able to significantly block the reduction in the immobility time elicited by UA. None of the treatments caused significant changes on locomotor activity in the open-field test (Fig. 1B) Based on these results, the sub-effective dose of fluoxetine (5 mg/kg) was selected to be used in association with a sub-effective dose of UA. Fig. 1E shows that the co-administration of sub-effective doses of UA (0.001 mg/kg, p.o.) and fluoxetine (5 mg/kg, p.o.) was able to produce an antidepressant-like response in the TST without causing alterations in the locomotor activity in the openfield test (Fig. 1F) . The two-way ANOVA showed a significant main effect for UA treatment [F(1,28) The results presented in Fig. 2A show that the pre-treatment with AMPT was able to prevent the antidepressant-like effect of UA in the TST. Fig. 2E show that the co-administration of sub-effective doses of UA (0.001 mg/kg, p.o.) and reboxetine (2 mg/kg, p.o.) was able to produce an antidepressant-like behavior in the TST without causing alterations on the locomotor activity in the open-field test (Fig. 2F) . The two-way ANOVA revealed a significant main effect for UA treatment [F(1,28) The results presented in Fig. 3C show that treatment of animals with a sub-effective dose of ketamine did not potentiate the effect of a subeffective dose of UA in the TST. None of the treatments altered the locomotor activity of mice (Fig. 3D) 
Involvement of the opioid system in the antidepressant-like effect of UA in the TST
The results presented in Fig. 4A show that the pre-treatment of the animals with naloxone was not able to prevent the antidepressantlike effect of UA in the TST and did not modify the ambulation in the open-field test (Fig. 4B) . The two-way ANOVA showed significant differences for UA treatment [F(1,28) 
Discussion
The results of this study show an involvement of the serotonergic and noradrenergic systems, but not glutamatergic or opioid systems, in the antidepressant-like effect of UA in the TST. This is a wellvalidated behavioral despair test useful for screening antidepressant drugs and the mechanisms underlying their antidepressant responses Steru et al., 1985) . In this test, mice are placed in an inescapable situation which leads to the development of an immobile posture and compounds that have antidepressant-like effect promote the occurrence of escape-related behavior decreasing the immobility time duration (Cryan et al., 2005) . To rule out the possibility that the reduction in immobility time produced by a given compound in the TST is due to an increased locomotor activity, animals are submitted to the open-field test (Rodrigues et al., 2002 (Rodrigues et al., , 1996 . In this work none of the treatments caused changes in spontaneous locomotion of mice, indicating that the results obtained in the TST were not due to any unspecific changes in locomotor activity. The lack of effect of UA in the open-field test is in agreement with literature data (Machado et al., 2012b; Verano et al., 2013) .
Several results demonstrate that plant extracts which have UA as one of their main constituents, such as Rosmarinus officinalis and Eugenia brasiliensis, display an antidepressant-like effect by a mechanism dependent upon the involvement of the monoaminergic systems Machado et al., 2013 Machado et al., , 2012a . Moreover, UA is one of the major compounds of the extract of Gardenia jasminoides fruits, which was reported to inhibit monoamine oxidases A and B and to increase brain serotonin concentrations in rats (Hwang, 2003; Hwang and Park, 2007) . UA isolated from G. jasminoides exhibited a significant inhibition of either monoamine oxidase B or dopamine β- hydroxylase, an enzyme that converts dopamine into norepinephrine (Kim et al., 2012) , somewhat in agreement with the fact that UA produces antidepressant-like effect in the TST, at least in part, through the activation of dopamine D 1 and D 2 receptors (Machado et al., 2012b) .
Many studies indicate that the biogenic amines (serotonin, norepinephrine and dopamine) play a pivotal role in the etiology of depression and on the effects of different antidepressant therapies (Elhwuegi, 2004) . Indeed, the therapeutic efficacy of commercially available antidepressants is dependent on the increase in the availability of monoamines in the brain caused by the treatment with these agents (Blier, 2001; Hamon and Blier, 2013) . Moreover, clinical studies have demonstrated that inhibition of serotonin, as well as norepinephrine and dopamine synthesis, induced clinical relapse in remitted patients and prevented the effect of antidepressant agents (Delgado et al., 1993 (Delgado et al., , 1999 (Delgado et al., , 1991 . In agreement, investigations for the last 30 years allowed the demonstration of the existence of functional interactions between serotonergic, noradrenergic and dopaminergic systems (Hamon and Blier, 2013) .
Regarding the serotonergic system, there are several evidences reporting that antidepressant therapy may relieve depression through an increased efficacy of the serotonergic neurotransmission (Elhwuegi, 2004; Hamon and Blier, 2013; Nemeroff and Owens, 2002) . The investigation about the effects of monoamine depletions on antidepressant activity is an important strategy for directly assessing the relative contribution of specific neurotransmitters to the behavioral effects of different antidepressant compounds (O'Leary et al., 2007) . In the present study, the administration of PCPA, a selective inhibitor of the rate-limiting enzyme in the biosynthesis of serotonin, tryptophan hydroxylase, was the approach used to deplete endogenous brain serotonin (Koe and Weissman, 1966; O'Leary et al., 2007) . This treatment was able to completely prevent the antidepressant-like effect of UA in the TST, indicating that its antidepressant-like effect is dependent on the availability of serotonin in the synaptic cleft. Reinforcing this hypothesis, the co-administration of sub-effective doses of UA in combination with fluoxetine produced a synergistic antidepressant-like response in the TST.
Experimental and clinical data also support a fundamental role of noradrenergic system in the etiology of depression and noradrenergic compounds have been extensively utilized in clinical practice (Elhwuegi, 2004; Hamon and Blier, 2013; Nemeroff and Owens, 2002) . Moreover, clinical evidence showed that AMPT, an inhibitor of dopamine and norepinephrine synthesis, produced a robust increase in the depressive symptoms assessed by the Hamilton depression rating scale (Miller et al., 1996) . In the present study, the pre-treatment of mice with AMPT abolished the antidepressant-like effect of UA in the TST. This result may be due to a reduction in the availability of norepinephrine and/or dopamine brain levels (Mayorga et al., 2001 ). To better address this issue, we also evaluated the effect of combined administration of subeffective doses of UA with reboxetine, a selective norepinephrine reuptake inhibitor. The synergistic antidepressant-like effect obtained using this experimental protocol indicates that the noradrenergic system is implicated in the antidepressant-like response of UA. The exact mechanism by which UA modulates the monoaminergic system and exerts its antidepressant-like effect is not yet fully elucidated. However, its inhibitory action on the activity of the enzymes monoamine oxidase B and dopamine β-hydroxylase suggests that UA acts by increasing the amount of monoamines stored and released from the nerve terminals.
Several studies support the involvement of the glutamatergic system in the pathophysiology of mood disorders as well as the efficacy of glutamatergic agents, such as NMDA receptor antagonists, as antidepressant agents (Layer et al., 1995; Trullas and Skolnick, 1990; Zarate et al., 2013) . Our work demonstrates that the pre-treatment of mice with NMDA was not capable of preventing the reduction of immobility time in the TST induced by the treatment of mice with UA. Conversely, the antidepressant-like responses of compounds that cause NMDA inhibition have been reported to be abolished by this same dose of NMDA in a similar experimental protocol Ludka et al., 2013; Moretti et al., 2011) . Therefore, our results suggest that an inhibition of NMDA receptors is probably not implicated in the effect of UA in the TST. Corroborating this conclusion, the treatment with subeffective doses of ketamine or MK-801, NMDA receptor antagonists, was not able to cause a synergistic antidepressant-like effect with a sub-effective dose of UA.
Pharmacological, neurochemical and behavioral findings support a role for endogenous opioids in mood disorders (Mansour et al., 1988; Pickar et al., 1980; Tejedor-Real et al., 1995) . Moreover, clinical trials indicate that opioid compounds such as β-endorphin and buprenorphine have antidepressant effects (Bodkin et al., 1995; Darko et al., 1992) and that depressed patients were reported to display a deficiency of endogenous opioid activity (Pickar et al., 1980) . Therefore, naloxone, an opioid receptor antagonist, is used to block the antidepressant-like effect of different pharmacological agents in preclinical studies. Studies showed that naloxone (1 mg/kg) was able to prevent the anti-immobility effect of several antidepressant compounds in the mouse forced swimming test (Brocardo et al., 2009; Brüning et al., 2011; Kaster et al., 2007; Zomkowski et al., 2005) , and at a wide dose range (0.5-2 mg/kg) abolished the antidepressant-like effect of codeine, an opioid agent, in the TST (Berrocoso et al., 2013) . In the present study, the administration of naloxone at 1 mg/kg did not prevent the antidepressant-like effect of UA in the TST, suggesting that the opioid system is also not involved in the antidepressant-like effect of UA. Noteworthy, somewhat in agreement with our study, a recent study demonstrated that the antinociceptive response of UA is mediated by serotonergic activation, and naloxone administration was not able to modify the antinociceptive profile of UA (Verano et al., 2013) .
The results reported herein suggest that the antidepressant-like effect of UA in the TST in mice is due to the participation of serotonergic and noradrenergic systems. Taking it together with previous data of our group that demonstrated the involvement of dopaminergic system in the UA effect (Machado et al., 2012b) , we conclude that brain monoamines should be sustained at a certain level to maintain UA antidepressant response, consistent with the notion that serotonergic, noradrenergic and dopaminergic systems concur in the therapeutic antidepressant efficacy (Hamon and Blier, 2013) . The most commonly prescribed antidepressants act by selectively increasing the synaptic availability of serotonin or norepinephrine, or through action on both (Shaw et al., 2007) . However, the antidepressants that act selectively on only one monoamine system alleviate depressive symptoms in a limited percentage of patients, and are poorly effective to prevent recurrence (Hamon and Blier, 2013) . Therefore, one strategy that has emerged in new antidepressant development is the use of triple reuptake inhibitors, which inhibit reuptake of serotonin, norepinephrine, and dopamine, and have been hypothesized to produce a more rapid onset of activity and better efficacy over single or dual reuptake inhibitor antidepressants (Liang et al., 2008) . Accordingly, UA can represent an interesting antidepressant agent to improve the speed of response, remission of symptoms, and quality of life for patients suffering from depression, since it exerts an antidepressant-like effect dependent on the modulation of serotonergic, noradrenergic and dopaminergic systems. Moreover, the synergistic antidepressant responses elicited by UA in combination with bupropion (Machado et al., 2012b) , fluoxetine and reboxetine suggest that this compound may improve the effectiveness of conventional antidepressants. Considering these findings together with the neuroprotective effect of UA reported in other studies (Hong et al., 2012; Li et al., 2013) , and its safe pharmacological profile (Aggarwal et al., 2004) , it is rational to consider UA as a useful agent to be further investigated for the treatment of depression. Therefore, studies are in progress to evaluate its antidepressant action in animal models of depression that mimic some symptoms of this disorder in mice. Furthermore, considering the antidepressant and antitumor activities of UA (Liu, 1995; Machado et al., 2012b; Zang et al., 2014) and the high rate of comorbidity between depression and cancer (O'Neill et al., 2014) , further studies regarding biological activities of the UA should be considered, especially regarding depression associated with cancer.
Conclusions
In summary, the results of this study show an involvement of the serotonergic and noradrenergic, but not glutamatergic or opioid systems, in the antidepressant-like effect elicited by oral administration of UA in the TST in mice. Moreover, the synergistic antidepressant responses elicited by UA in combination with conventional antidepressants suggest that this compound may improve their effectiveness, a finding that may be of therapeutic relevance.
